Anti-RAR beta Antibody
- 产品详情
- 实验流程
Application
| WB, IHC, IP |
|---|---|
| Primary Accession | P10826 |
| Reactivity | Human, Mouse, Rat, Bovine, Dog |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 50489 Da |
| Gene ID | 5915 |
|---|---|
| Other Names | HAP; NR1B2; Retinoic acid receptor beta; RAR-beta; HBV-activated protein; Nuclear receptor subfamily 1 group B member 2; RAR-epsilon |
| Target/Specificity | KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human RAR beta. The exact sequence is proprietary. |
| Dilution | WB~~WB (1/500 - 1/1000) IHC~~1:100~500 IP~~N/A |
| Format | Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. |
| Storage | Store at -20 °C.Stable for 12 months from date of receipt |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | RARB |
|---|---|
| Synonyms | HAP, NR1B2 |
| Function | Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors (PubMed:12554770). The RXRA/RARB heterodimer can act as a repressor on the DR1 element and as an activator on the DR5 element (PubMed:29021580). In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). |
| Cellular Location | Nucleus. Cytoplasm [Isoform Beta-2]: Nucleus. |
| Tissue Location | Expressed in aortic endothelial cells (at protein level). |
Research Areas
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
REFERENCES
Benbrook D.,et al.Nature 333:669-672(1988).
de The H.,et al.Nature 330:667-670(1987).
Sommer K.M.,et al.Proc. Natl. Acad. Sci. U.S.A. 96:8651-8656(1999).
Shen S.,et al.DNA Seq. 2:111-119(1991).
Houle B.,et al.Cancer Res. 54:365-369(1994).
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
¥ 1,250.00
Cat# AP51466
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。